A Phase II/ III trial evaluating safety and efficacy of Imigliptin Hydrochloride (KBP-3853).
Not yet recruiting
Phase of Trial: Phase II/III
Latest Information Update: 20 Sep 2016
At a glance
- Drugs Imigliptin (Primary)
- Indications Type 2 diabetes mellitus
- Focus Therapeutic Use
- 20 Sep 2016 New trial record
- 04 Aug 2016 According to a XuanZhu Pharma media release, this trial has been approved by CFDA.